当前位置： SCI文献检索 > BMC Medical Genomics期刊下所有文献 > Development of somatic mutation signatures for risk stratification and prognosis in lung and colorectal adenocarcinomas.

Development of somatic mutation signatures for risk stratification and prognosis in lung and colorectal adenocarcinomas.

Abstract：

BACKGROUND:Prognostic signatures are vital to precision medicine. However, development of somatic mutation prognostic signatures for cancers remains a challenge. In this study we developed a novel method for discovering somatic mutation based prognostic signatures. RESULTS:Somatic mutation and clinical data for lung adenocarcinoma (LUAD) and colorectal adenocarcinoma (COAD) from The Cancer Genome Atlas (TCGA) were randomly divided into training (n = 328 for LUAD and 286 for COAD) and validation (n = 167 for LUAD and 141 for COAD) datasets. A novel method of using the log2 ratio of the tumor mutation frequency to the paired normal mutation frequency is computed for each patient and missense mutation. The missense mutation ratios were mean aggregated into gene-level somatic mutation profiles. The somatic mutations were assessed using univariate Cox analysis on the LUAD and COAD training sets separately. Stepwise multivariate Cox analysis resulted in a final gene prognostic signature for LUAD and COAD. Performance was compared to gene prognostic signatures generated using the same pipeline but with different somatic mutation profile representations based on tumor mutation frequency, binary calls, and gene-gene network normalization. Signature high-risk LUAD and COAD cases had worse overall survival compared to the signature low-risk cases in the validation set (log-rank test p-value = 0.0101 for LUAD and 0.0314 for COAD) using mutation tumor frequency ratio (MFR) profiles, while all other methods, including gene-gene network normalization, have statistically insignificant stratification (log-rank test p-value ≥0.05). Most of the genes in the final gene signatures using MFR profiles are cancer-related based on network and literature analysis. CONCLUSIONS:We demonstrated the robustness of MFR profiles and its potential to be a powerful prognostic tool in cancer. The results are robust according to validation testing and the selected genes are biologically relevant.

journal_name

BMC Med Genomics

journal_title

BMC medical genomics

authors

Menor M,Zhu Y,Wang Y,Zhang J,Jiang B,Deng Y

doi

10.1186/s12920-018-0454-7

subject

Has Abstract

pub_date

2019-01-31 00:00:00

pages

issue

Suppl 1

issn

1755-8794

pii

10.1186/s12920-018-0454-7

journal_volume

pub_type

杂志文章

在线工具

Development of somatic mutation signatures for risk stratification and prognosis in lung and colorectal adenocarcinomas.